美國一項最新研究發(fā)現(xiàn),，如果體內胰島素水平過高，婦女絕經(jīng)后罹患乳腺癌的風險可能會增加,。

美國愛因斯坦醫(yī)學院的研究人員在23日出版的《癌癥雜志》網(wǎng)絡版上報告說,，他們對5450名婦女的胰島素水平和乳腺癌患病情況進行了分析。結果發(fā)現(xiàn),，體內胰島素水平最高的婦女患乳腺癌的幾率是胰島素水平最低婦女的兩倍,。與體態(tài)偏胖的婦女相比，那些體態(tài)偏瘦的婦女更容易因胰島素水平過高而罹患乳腺癌,。

研究人員建議,，女性在絕經(jīng)后應通過適當鍛煉等方式使胰島素保持在正常水平，降低乳腺癌的發(fā)病風險,。

胰島素是一種蛋白質類激素,，在調節(jié)機體糖代謝、脂肪代謝和蛋白質代謝方面發(fā)揮著重要作用,。（生物谷Bioon.com）

生物谷推薦原始出處：

International Journal of Cancer 2 Jun 2009

Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer

Geoffrey C. Kabat 1 *, Mimi Kim 1, Bette J. Caan 2, Rowan T. Chlebowski 3, Marc J. Gunter 1, Gloria Y.F. Ho 1, Beatriz L. Rodriguez 4, James M. Shikany 5, Howard D. Strickler 1, Mara Z. Vitolins 6, Thomas E. Rohan 1

1Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY
2Division of Research, Kaiser Permanente of Northern California, Oakland, CA
3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
4Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI
5Division of Preventive Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL
6Department of Epidemiology and Prevention, School of Medicine, Wake Forest University, Winston Salem, NC

Experimental and epidemiological evidence suggests that circulating glucose and insulin may play a role in breast carcinogenesis. However, few cohort studies have examined breast cancer risk in association with glucose and insulin levels, and studies to date have had only baseline measurements of exposure. We conducted a longitudinal study of postmenopausal breast cancer risk using the 6% random sample of women in the Women's Health Initiative clinical trials whose fasting blood samples, provided at baseline and at years 1, 3 and 6, were analyzed for glucose and insulin. In addition, a 1% sample of women in the observational study, who had glucose and insulin measured in fasting blood samples drawn at baseline and in year 3, were included in the analysis. We used Cox proportional hazards models to estimate hazard ratios and 95% confidence intervals for the association of baseline and follow-up measurements of serum glucose and insulin with breast cancer risk. All statistical tests were 2-sided. Among 5,450 women with baseline serum glucose and insulin values, 190 incident cases of breast cancer were ascertained over a median of 8.0 years of follow-up. The highest tertile of baseline insulin, relative to the lowest, was associated with a 2-fold increase in risk in the total population (multivariable hazard ratio 2.22, 95% confidence interval 1.39-3.53) and with a 3-fold increase in risk in women who were not enrolled in the intervention arm of any clinical trial (multivariable hazard ratio 3.15, 95% confidence interval 1.61-6.17). Glucose levels showed no association with risk. Analysis of the repeated measurements supported the results of the baseline analysis. These data suggest that elevated serum insulin levels may be a risk factor for postmenopausal breast cancer.